Effectiveness Study of Zymar Versus Vigamox for Preoperative Sterilization of the Ocular Surface After Loading Dose

The recruitment status of this study is unknown because the information has not been verified recently.

Verified June 2006 by Ophthalmic Consultants of Boston. Recruitment status was Active, not recruiting

First Received on June 30, 2006. Last Updated on July 3, 2006 History of Changes

Sponsor:	Ophthalmic Consultants of Boston
Collaborator:	Allergan
Information provided by:	Ophthalmic Consultants of Boston
ClinicalTrials.gov Identifier:	NCT00347828

Purpose

The purpose of this study is to analyze the effect of Zymar and Vigamox on ocular surface bacteria. We believe that Zymar will eradicate more ocular surface bacteria than Vigamox.

Condition	Intervention	Phase
Eye Infection Infection	Drug: Moxifloxacin ophthalmic solution 0.5% Drug: Gatifloxacin ophthalmic solution 0.3%	Phase IV

Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Single Group Assignment Masking: Double-Blind Primary Purpose: Prevention
Official Title:	Prospective Study Comparing the Effectiveness of Zymar and Vigamox for Preoperative Antibiotic Sterilization of the Ocular Surface After Loading Dose

Resource links provided by NLM:

MedlinePlus related topics: Antibiotics Eye Infections

Drug Information available for: Gatifloxacin Moxifloxacin Moxifloxacin hydrochloride

U.S. FDA Resources

Further study details as provided by Ophthalmic Consultants of Boston:

Primary Outcome Measures:

Evidence of growth and number of colonies of bacteria on chocolate agar prior to antibiotic administration, t=0 hrs
Evidence of growth and number of colonies of bacteria on blood agar prior to antibiotic administration, t=0 hrs
Evidence of growth and number of colonies of bacteria on chocolate agar post-antibiotic administration, t=1 hr
Evidence of growth and number of colonies of bacteria on blood agar post-antibiotic administration, t=1 hr

Estimated Enrollment:	40
Study Start Date:	June 2006
Estimated Study Completion Date:	June 2006

Detailed Description:

Topical antibiotics are frequently used before surgical procedures with the intent of targetting and reducing the number of bacteria on the surface of the eye. These bacteria serve as potential sources for post-operative infection. One commonly used method is the administration of antibiotic drops 3 times: 1 hour prior to surgery at intervals of 5 minutes. Studies in the lab have shown that the preservative benzalkonium chloride 0.005%, part of the Zymar antibiotic drop preparation, allows the antibiotic to act more effectively than the antibiotic Vigamox, which does not include this preservative.

Comparison: The effect of Zymar antibiotic eye drops on conjunctival cultures compared to the effect of Vigamox on conjunctival cultures as measured by conjunctival cultures taken prior to treatment and then one hour after administration of eye drops 3 times, at 5 minute intervals.

Eligibility

Ages Eligible for Study:	25 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Male or female 25 years of age or older
Informed consent
Likely to complete the entire course of the study

Exclusion Criteria:

Contraindications or known sensitivity to any component of the study medications
A subject on oral or topical antibiotics
A subject that has a condition (i.e. an uncontrolled systemic disease) or is in a situation which, in the investigator's opinion, may put the subject at significant risk, may confound the trial results, or may interfere significantly with the subject's participation in the trial.
Monocular subjects
Contact lens wearers
Subjects who regularly take eyedrops other than preservative free artificial tears
A subject with an eye infection

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00347828

Locations

United States, Massachusetts
Ophthalmic Consultants of Boston
Boston, Massachusetts, United States, 02114

Sponsors and Collaborators

Ophthalmic Consultants of Boston

Allergan

Investigators

Principal Investigator:	Michael B Raizman, B.A./M.D.	Ophthalmic Consultants of Boston
Study Director:	Sandra Y Cho, B.A./M.D.	New England Eye Center/Tufts-New England Medical Center
Study Director:	Rahul Mandiga, B.S.	New England Eye Center/Tufts-New England Medical Center

More Information

No publications provided

ClinicalTrials.gov Identifier:	NCT00347828 History of Changes
Other Study ID Numbers:	Allergan/Z101
Study First Received:	June 30, 2006
Last Updated:	July 3, 2006
Health Authority:	United States: Institutional Review Board

Keywords provided by Ophthalmic Consultants of Boston:

Antibiotic prophylaxis
Vigamox
Moxifloxacin
Zymar

Gatifloxacin
Preoperative antibiotic
Eye infection

Additional relevant MeSH terms:

Eye Infections
Infection
Eye Diseases
Anti-Bacterial Agents
Fluoroquinolones
Disinfectants
Gatifloxacin
Moxifloxacin
Norgestimate, ethinyl estradiol drug combination
Anti-Infective Agents
Therapeutic Uses

Pharmacologic Actions
Nucleic Acid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Contraceptives, Oral, Combined
Contraceptives, Oral
Contraceptive Agents, Female
Contraceptive Agents
Reproductive Control Agents
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on February 09, 2012